A novel component of cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro

[1]  Benjamin J. Whalley,et al.  Medicinal cannabis: is Δ9–tetrahydrocannabinol necessary for all its effects? , 2003 .

[2]  S. Doggrell,et al.  Treatment of dementia with neurotransmission modulation , 2003, Expert opinion on investigational drugs.

[3]  A. Hoffman,et al.  Functional localization of cannabinoid receptors and endogenous cannabinoid production in distinct neuron populations of the hippocampus , 2003, The European journal of neuroscience.

[4]  F. Grotenhermen,et al.  Survey on the Medical Use of Cannabis and THC in Germany , 2003 .

[5]  E. Levine,et al.  Cannabinoids depress inhibitory synaptic inputs received by layer 2/3 pyramidal neurons of the neocortex. , 2002, Journal of neurophysiology.

[6]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[7]  Á. Pazos,et al.  Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. , 2002, European journal of pharmacology.

[8]  R. Nicoll,et al.  Endocannabinoid Signaling in the Brain , 2002, Science.

[9]  D. Yurgelun-Todd,et al.  Neuropsychological performance in long-term cannabis users. , 2001, Archives of general psychiatry.

[10]  G. Gessa,et al.  Effects of chronic Δ9-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze , 2001, Neuropharmacology.

[11]  K. Hsu,et al.  Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons , 2001, The Journal of physiology.

[12]  A. Zimmer,et al.  Enhanced acetylcholine release in the hippocampus of cannabinoid CB1 receptor‐deficient mice , 2001, British journal of pharmacology.

[13]  T. Wenger,et al.  Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study☆ , 2000, Peptides.

[14]  M. Mark,et al.  G-protein mediated gating of inward-rectifier K+ channels. , 2000, European journal of biochemistry.

[15]  R. Pertwee.  Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development , 2000, Expert opinion on investigational drugs.

[16]  R. Hampson,et al.  Cannabinoid receptor activation in CA1 pyramidal cells in adult rat hippocampus , 2000, Brain Research.

[17]  F. Grotenhermen,et al.  [Results of a standardized survey on the medical use of cannabis products in the German-speaking area]. , 1999, Forschende Komplementarmedizin.

[18]  M. Parmentier,et al.  Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. , 1999, Science.

[19]  M. Postlethwaite,et al.  Muscarinic agonist-induced burst firing in immature rat olfactory cortex neurons In vitro. , 1998, Journal of neurophysiology.

[20]  C. Chavkin,et al.  Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes , 1995, Neuroscience Letters.

[21]  A. Constanti,et al.  Persistent muscarinic excitation in guinea-pig olfactory cortex neurons: Involvement of a slow post-stimulus afterdepolarizing current , 1993, Neuroscience.

[22]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[23]  S. A. Turkanis,et al.  Effects of δ9-Tetrahydrocannabinol on cat spinal motoneurons , 1983, Brain Research.

[24]  E. Carlini,et al.  Hypnotic and Antiepileptic Effects of Cannabidiol , 1981, Journal of clinical pharmacology.

[25]  M. Elsohly,et al.  Constituents of Cannabis sativa L. XVII. A review of the natural constituents. , 1980, Journal of natural products.

[26]  G. Sharma,et al.  Constituents of Cannabis sativa , 1979 .

[27]  J. Ludovic Croxford,et al.  Therapeutic Potential of Cannabinoids in CNS Disease , 2003, CNS drugs.

[28]  P. Blier,et al.  Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. , 2001, Journal of psychiatry & neuroscience : JPN.

[29]  Schouten Jt.  Medical marijuana: legal considerations. , 1999 .

[30]  J. Brust,et al.  Marijuana use and the risk of new onset seizures. , 1992, Transactions of the American Clinical and Climatological Association.